But for Tim Friede, a self-taught venom expert from Wisconsin, the answer came after two decades of deliberate, repeated exposure to some of the deadliest snakes in the world. Years of extreme self-immunization-more than 200 bites and hundreds of controlled venom injections-have turned his immune system into a rare biological archive of antitoxin antibodies, now at the center of a groundbreaking medical development.
According to the World Health Organization, snakebite envenoming is a global health crisis: it kills between 81,000 and 138,000 people annually and leaves up to 400,000 with permanent disabilities. The impact also falls disproportionately on rural communities in Africa, Asia, and Latin America where access to timely, species-specific antivenoms is limited. Conventional antivenoms, developed since the late 19th century, rely on antibodies harvested from horses or sheep immunized with venom from one single species. Although effective, these treatments are often region-specific, require an exact identification of the snake involved, and carry risks of severe immune reactions because of their non-human origin.
Friede’s immune history offered an unprecedented alternative: Through a cycle of venoms from 16 lethal species, including the black mamba, king cobra, coastal taipan, and kraits, his body produced antibodies capable of neutralizing multiple toxin types. Jacob Glanville, CEO of Centivax, recognized the potential: “Not only did he potentially create these broadly neutralizing antibodies, in this case, it could give rise to a broad-spectrum or universal antivenom.” Along with structural biologist Peter Kwong at Columbia University, the team isolated two standout antibodies-LNX-D09, which targeted long-chain neurotoxins, and SNX-B03, which bound short-chain neurotoxins.
These were combined with varespladib, a small-molecule inhibitor of the PLA2 enzymes. PLA2 toxins are a common component of many venoms and induce muscle damage, inflammation, and coagulopathy; however, they are poorly neutralized by conventional antivenoms due to low immunogenicity in production animals. As shown in preclinical studies, varespladib’s inhibitory action protects against lethal doses of both viperid and elapid venoms, making it an ideal complement to Friede’s antibodies.
The resulting three-component cocktail was tested against a WHO diversity panel of 19 medically important elapid species. In mouse models, it provided complete protection against 13 species, including black mamba, king cobra, tiger snake, and common krait, and partial protection against six others. Stru81,000 and 138,000 people annuallyctural analyses revealed that the antibodies mimic the binding interface of the nicotinic acetylcholine receptor, blocking neurotoxins from inducing paralysis. Varespladib extended coverage to species whose lethality depends on PLA2 activity, such as the inland taipan.
The implications are profound. Because a broad-spectrum antivenom might be given even when the offending snake is unknown-a common occurrence in rural clinics-it would also skirt the logistical and safety hurdles of animal-derived sera to provide a human-compatible therapy with much-reduced risk of serum sickness. Furthermore, the modular approach-targeting conserved toxin families-opens the door to parallel development for vipers, whose venoms rely on tissue-destructive metalloproteinases and serine proteases.
Centivax plans to start field trials in Australia, where elapids are the only venomous family, by treating dogs brought into veterinary clinics with snakebite injuries. Success there could pave the way for human trials and eventual deployment in high-burden regions. Glanville says the market potential, estimated at $600 million a year, is secondary to the humanitarian impact: “Although there are millions of snake envenomations per year, the majority are in the developing world, disproportionately affecting rural communities.”
